749 related articles for article (PubMed ID: 30772776)
1. Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes.
Morean ME; Lederman IR
Addict Behav; 2019 Jun; 93():233-239. PubMed ID: 30772776
[TBL] [Abstract][Full Text] [Related]
2. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Mead A
Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
[TBL] [Abstract][Full Text] [Related]
3. Mapping cannabis potency in medical and recreational programs in the United States.
Cash MC; Cunnane K; Fan C; Romero-Sandoval EA
PLoS One; 2020; 15(3):e0230167. PubMed ID: 32214334
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated with Medical Cannabis Use After Certification: A Three-Month Longitudinal Study.
Zhang C; Slawek DE; Ross J; Zolotov Y; Castillo F; Levin FR; Sohler NL; Minami H; Cunningham CO; Starrels JL; Arnsten JH
Cannabis Cannabinoid Res; 2024 Jun; 9(3):e859-e869. PubMed ID: 36961410
[No Abstract] [Full Text] [Related]
5. Marijuana use among patients with epilepsy at a tertiary care center.
Kerr A; Walston V; Wong VSS; Kellogg M; Ernst L
Epilepsy Behav; 2019 Aug; 97():144-148. PubMed ID: 31252269
[TBL] [Abstract][Full Text] [Related]
6. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
[TBL] [Abstract][Full Text] [Related]
7. The impacts of potency, warning messages, and price on preferences for Cannabis flower products.
Shi Y; Cao Y; Shang C; Pacula RL
Int J Drug Policy; 2019 Dec; 74():1-10. PubMed ID: 31382201
[TBL] [Abstract][Full Text] [Related]
8. Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.
Dobbins M; Rakkar M; Cunnane K; Pennypacker SD; Wagoner KG; Reboussin BA; Romero-Sandoval EA
Front Public Health; 2022; 10():893009. PubMed ID: 35784239
[TBL] [Abstract][Full Text] [Related]
9. Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults.
Dunbar MS; Seelam R; Tucker JS; Firth CL; Pedersen ER; Klein DJ; Rodriguez A; D'Amico EJ
Addict Behav; 2022 Mar; 126():107185. PubMed ID: 34839070
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.
Fedorova EV; Wong CF; Ataiants J; Iverson E; Conn BM; Lankenau SE
Drug Alcohol Depend; 2021 Apr; 221():108648. PubMed ID: 33676073
[TBL] [Abstract][Full Text] [Related]
11. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
12. Cannabis in Parkinson's Disease: The Patients' View.
Yenilmez F; Fründt O; Hidding U; Buhmann C
J Parkinsons Dis; 2021; 11(1):309-321. PubMed ID: 33216043
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Dispensing and Utilization Patterns of Medical Cannabis Products in State Licensed Cannabis Dispensaries.
Tanco K; Olson A; Fellman B; Jankowski M; Lai SY; Shete S; Harbison K; Scheid J; Bruera E
J Palliat Med; 2023 Nov; 26(11):1482-1487. PubMed ID: 37285183
[No Abstract] [Full Text] [Related]
14. [CHARACTERISTICS OF MEDICAL CANNABIS USAGE AMONG PATIENTS WITH FIBROMYALGIA].
Habib G; Levinger U
Harefuah; 2020 May; 159(5):343-348. PubMed ID: 32431124
[TBL] [Abstract][Full Text] [Related]
15. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours.
Pacula RL; Jacobson M; Maksabedian EJ
Addiction; 2016 Jun; 111(6):973-80. PubMed ID: 26687431
[TBL] [Abstract][Full Text] [Related]
16. Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain.
Boehnke KF; Scott JR; Litinas E; Sisley S; Clauw DJ; Goesling J; Williams DA
J Pain; 2019 Nov; 20(11):1362-1372. PubMed ID: 31132510
[TBL] [Abstract][Full Text] [Related]
17. A Twitter-based survey on marijuana concentrate use.
Daniulaityte R; Zatreh MY; Lamy FR; Nahhas RW; Martins SS; Sheth A; Carlson RG
Drug Alcohol Depend; 2018 Jun; 187():155-159. PubMed ID: 29669296
[TBL] [Abstract][Full Text] [Related]
18. Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder.
Williams AR; Santaella-Tenorio J; Mauro CM; Levin FR; Martins SS
Addiction; 2017 Nov; 112(11):1985-1991. PubMed ID: 28600874
[TBL] [Abstract][Full Text] [Related]
19. Cannabis for Chronic Pain: Challenges and Considerations.
Romero-Sandoval EA; Fincham JE; Kolano AL; Sharpe BN; Alvarado-Vázquez PA
Pharmacotherapy; 2018 Jun; 38(6):651-662. PubMed ID: 29637590
[TBL] [Abstract][Full Text] [Related]
20. The implications of the use of cannabidiol-related products in a safety-sensitive drug testing environment: A medical-legal perspective.
Jooste J; Laurens JB; Jordaan M; Marais AAS; Curlewis LG
S Afr Med J; 2021 Oct; 111(10):942-945. PubMed ID: 34949286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
